Genvor, Inc. (OTCQB:GNVR) is a biotechnology company harnessing AI to generate novel peptides xqthat deliver high-performance solutions across agriculture and human health. Genvor's proprietary BioCypher platform designs peptides that enhance crop performance, reduce chemical inputs, and support human recovery and wellness. Through strategic partnerships and a dual-market commercialization model, Genvor is advancing peptide science from field to finish line. For more information, visit www.genvor.com.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company developing cancer treatments using its proprietary INTASYL® technology, a patented form of siRNA (short interfering RNA) gene silencing that works by silencing specific genes that allow tumors to evade the immune system. Rather than attacking cancer cells directly, INTASYL reactivates the body's own T cells, a type of immune cell, so they can more effectively identify and kill tumors. Phio's lead program, PH-762, targets the PD-1 gene in skin cancer and completed the treatment phase of a Phase 1b clinical trial in January 2026, with 22 patients treated across five escalating dose cohorts. A second program, PH-894, targets the BRD4 gene across a broader range of cancers and has completed the studies required to file for FDA clearance to begin clinical testing. Phio holds 59 issued patents with protection extending to 2044 and carries no debt.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage pharmaceutical company built around JOTROL, a patented resveratrol formulation that has demonstrated materially higher bioavailability than earlier versions of the compound. Based in Jupiter, Florida, the company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and central nervous system disorders while commercializing Nugevia, a premium longevity supplement line using the same delivery technology. On the pharmaceutical side, the FDA cleared the company's IND application in November 2025, authorizing a Phase 2A clinical trial in Parkinson's disease. The company is also exploring potential applications in Alzheimer's disease, Friedreich's Ataxia, Mucopolysaccharidoses Type I, and MELAS. Jupiter's consumer business launched in 2025 with three Nugevia products (GLO, PWR, and MND), each targeting pillars of healthy aging. Jupiter completed its IPO in December 2024 and is led by Christer Rosén, Founder, Chairman, and CEO.

My Size, Inc. (NASDAQ: MYSZ) is a fashion-tech company built around three businesses that tackle two expensive problems in online retail: shoppers buying the wrong size and brands getting stuck with too much inventory. Founded and headquartered in Israel with operations across the U.S. and Europe, My Size operates Naiz Fit, a software platform that helps fashion brands reduce returns and increase sales by recommending the right size to each shopper; Percentil, a managed secondhand marketplace serving consumers and brands across Spain, France, Germany, and Italy; and Orgad, a U.S.-based retailer that moves overstock and liquidation inventory through Amazon and other online channels. In fiscal year 2024, the Company generated $8.26 million in revenue, an 18% increase over the prior year, and reported a 37% reduction in net losses. My Size expects approximately $10 million in revenue for 2025 and is targeting operating profitability in 2026.

Ethema Health Corporation (OTCID: GRST) provides in-patient treatment for adults with substance use disorders, operating treatment facilities in Florida and Kentucky. Based in West Palm Beach, the company runs detoxification and residential rehabilitation programs through its Evernia Health Center subsidiary in West Palm Beach and Boca Raton, Florida, and through its Aria Kentucky subsidiary, which operates addiction treatment centers in Morehead and Paducah, Kentucky.

Ethema has been active in addiction treatment since 2010, initially through operations in Ontario, Canada, before transitioning to the U.S. market. The company's combined operations generated approximately $14 million in revenue for the nine months ended September 30, 2025, driven by the January 2025 acquisition of the Edgewater Recovery Centers business in Kentucky and continued organic growth at its Florida locations. The company is led by CEO Shawn Leon, who has more than 25 years of experience managing public and private companies across healthcare, hospitality, real estate, and capital markets.

eXoZymes Inc. (Nasdaq: EXOZ) is a biotechnology company that has developed a new way to produce chemicals without using living cells. The company's technology, called "exozymes," combines enzymes (proteins that speed up chemical reactions) with artificial intelligence to create a manufacturing platform that transforms biomass into chemicals, medicines, and fuels. Unlike traditional synthetic biology that relies on living cells, eXoZymes' cell-free approach operates more like industrial chemistry, avoiding the common problems that prevent biological manufacturing from reaching commercial scale.

Create engaging experiences for your biggest fans – meet & greets, Q&A's, soundcheck parties and more.

Leveraging technologies that support a Digital Thread and Digital Transformation Strategies in Manufacturing. 3 HTi has a portfolio of clients in many manufacturing industries such as Medical, Aerospace and Defense, Automotive.

Acclara AI is modernising technical accounting workflows with cutting-edge AI solutions. Our solutions optimise accounting research today and the actual drafting of analysis tomorrow.

Adapt Ready’s ground-breaking risk intelligence platform delivers new data insights and fills in key gaps with external data, enabling our customers to better manage operational and financial risks, and to enhance their growth and profitability. With our platform, organizations can gain insights from external data tailored to specific situations before, during and after a crisis:

Before: Plan for risks by uncovering as many hidden risks as possible

During: Mitigate the impact – as events unfold, new data emerges and can inform decisions to reduce the event’s impact

After: Adapt to new conditions and refine future business direction

Adnexus is a Texas-based biotech company committed to the development and commercialization of its proprietary proteins and monoclonal antibodies for the treatment of infectious diseases.

Post-surgery breathing exercise management for patients and healthcare providers

Current therapeutic spirometry used after all inpatient surgeries relies on outdated mechanical devices, patient self-administration and reporting, and nursing-intensive bedside monitoring.

Andromeda Health Corp. was incorporated in May 2022, in Florida, as a C Corporation. The Company is headquartered in New York (at 401 Park Avenue S, Floor 10, New York, NY 10128) and has presence in Nashville, Dallas and Chicago, through its local partners who serve as the Company's representatives, advisors, liaisons, salesmen and investors, at the same time. The Company owns the title to all of its proprietary technology, respective intellectual property for which has been contributed by its founder, president and CEO - David Vakhtangishvili, upon the Company's incorporation back in 2022. So far the Company has raised $3.6 million in its first-ever, Seed Funding Round from a single investor and employs 30 professionals, majority of which represent very talented and experienced cloud and solution architects, engineers, coders, product managers, UX/UI designers, testers, etc. We are focused on building best quality products for ultimate user happiness.

Arrive AI's (Nasdaq: ARAI) patented last mile (ALM) platform enables drone- or ground robot-based and human mail delivery to and from a physical smart mailbox, while providing tracking data, smart logistics alerts and advanced chain of custody controls to secure the last-mile delivery for all shippers, delivery services, and autonomous delivery networks. Arrive AI makes the exchange of goods between people, robots, and drones frictionless, efficient and convenient through artificial intelligence, autonomous technology and interoperability with smart devices including doorbells, lighting and security systems. Learn more about the company at www.arriveai.com. See our press kit here: https://www.dropbox.com/scl/fo/1hngbr3n0csio41as3zq2/AIFvqWlgye-qVgIOPG2BcUQ?rlkey=3q1ipgjt1he9ktcvd4vh0vl5t&st=6a2jrjxm&dl=0

AVAX One Technology Ltd. (NASDAQ: AVX) is the first publicly traded Avalanche Treasury company, building the premier institutional gateway to the onchain financial economy powered by the Avalanche blockchain network. Through AVAX accumulation, onchain yield, and strategic acquisitions, the Company aims to compound long-term value for its shareholders while supporting the growth of the Avalanche ecosystem. Led by a team of veterans from institutional finance and public company backgrounds and advised by leaders from across the digital asset industry, AVAX One is being built to be a scalable, regulated gateway for public market investors to participate in the growth of the onchain economy. For more information, visit www.avax-one.com.

BitFuFu Inc. is a world-leading Bitcoin miner and mining services innovator. BitFuFu is committed to empowering the global Bitcoin network through its industry-leading cloud mining platform, rapidly scaling infrastructure, and innovative mining services.

For more information, please visit https://ir.bitfufu.com or follow BitFuFu on X @BitFuFuOfficial.

A world-class team of neuroscientists, AI researchers, and healthcare experts united by a mission to decode the brain and transform patient care.

Our 3D BioPrinted Tissue platform technology is built to scale and redefine the future of human tissue repair

Our mission at Burro is to solve the labor problem facing farmers by making robots like Wall-E a reality. To do this, we are starting first with a collaborative robotic platform called Burro, that helps people work more productively today, while building the base for more expansive autonomy where it is needed most. We believe this is the path towards a future where farming is fully autonomous.

To give every business and agency the power of a world-class marketing strategist—without the cost or complexity—by turning raw data into decisions, and marketing noise into clarity.

Our vision is to democratize cell-based therapies for all patients.

Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' cell therapies as ‘drugs’ for oncology and regenerative medicine applications.

We are developing a transgene-free “super-donor” stem cell platform designed to reprogram cell fate and function for the treatment of serious and currently incurable diseases.

Cell BioEngines’ competitive edge lies in scalable manufacturing of chemically reprogrammed stem cells without genetic engineering, combined with HLA-guided design and a population-informed biobank for broad patient coverage.

“Chaince Digital Brings Finance On-Chain.”

Chaince Digital Holdings Inc. (Nasdaq: CD) (formerly Mercurity Fintech Holding Inc.) is a digital finance and technology company focused on tokenization, on-chain innovation and regulated brokerage services. Through its subsidiaries, including Chaince Securities, LLC, a FINRA-registered broker-dealer, and AI/HPC infrastructure platforms, Chaince Digital provides technology-enabled solutions across distributed computing, business consulting and capital-markets services. The Company aims to bridge traditional financial markets with the emerging digital-asset economy through compliant, scalable and institutional-grade infrastructure.

For more information, please visit www.chaincedigital.com.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 74.8% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

Cloud Counselage Pvt. Ltd. is an award-winning IT & Management Consulting Company with a social cause to solve unemployability. Led by founders who have delivered projects across 120 countries, are now building a global ecosystem of 100 MN+ Professionals, 1 MN+ Companies, and 1 Lakh+ colleges across 100+ Countries to bring 85 Million global jobs to India by 2030, thereby bringing billion-dollar businesses to India.

CoinShares is a leading global asset manager specializing in digital assets, that delivers a broad range of financial services across investment management, trading and securities to a wide array of clients that includes corporations, financial institutions and individuals. Focusing on crypto since 2013, the firm is headquartered in Jersey, with offices in France, Sweden, Switzerland, the UK and the US. Relevant entities in the CoinShares group are regulated and/or authorized in Jersey by the Jersey Financial Services Commission, in France by the Autorité des marchés financiers, and in the US by the Securities and Exchange Commission, National Futures Association and Financial Industry Regulatory Authority. CoinShares PLC is publicly listed on the Nasdaq under the ticker CSHR.

we are cypherpunk — a company dedicated to privacy and self-sovereignty

DeFi Development Corp. is the first NASDAQ-listed (NASDAQ: DFDV) Digital Asset Treasury (DAT) designed with the explicit goal of accumulating and maximizing returns on Solana (SOL).

Leveraging capital markets, validator operations, on-chain innovation, and strategic partnerships to provide market participants with the optimal way to maximize SOL investment returns.

Dextego empowers people, teams, and leaders to thrive by delivering intelligent, personalized coaching at scale. We believe coaching should be a right, not a privilege, accessible to everyone, everywhere, exactly when it’s needed.

By blending behavioral science, predictive analytics, and AI, Dextego helps individuals develop real skills through practice and reflection, while enabling organizations to build cultures of continuous growth, stronger leadership, and measurable performance.

Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, is focused on providing and managing modular data center colocation facilities and infrastructure solutions. Through its wholly owned subsidiaries Duos Edge AI, Inc., and Duos Technology Solutions, Inc. the Company delivers high function computing infrastructure at the “Edge” designed to support high power computing facilities suitable for AI and Enterprise Computing. Duos is strategically focused on scaling its edge data center platforms in conjunction with its data center infrastructure solutions business. It provides manufacturer-agnostic sourcing, and fulfillment services to support efficient deployment of data centers and IT environments. Together, these platforms position the Company to address the growing demand for distributed digital infrastructure, while continuing to support legacy applications in Tier 3 and Tier 4 markets.

We aim to raise the capacity of our employees, clients, and partners through a high degree of integrity, transparency, and speed.

What does that mean? We aim to create a company culture that ensures our clients, employees, and partners are prosperous in their daily work. We believe in "empower others and do no harm." Doing well by each day, improving every day.

We commit to getting it right, no matter what it takes. We believe in being upfront, transparent, and forthright about whatever needs to be overcome. We don't shy away from obstacles in the road - we see them as opportunities to achieve incremental lift or discover new edges of what is truly possible.

We aim to make the difficult task of "getting your data right" easier and fully transparent. We've built a technology platform on which businesses could be built. It all starts with data movement and the foundational layer of data infrastructure that enables your success.

From solving equations with language models to building the verified runtime for autonomous enterprise systems, every step has been deliberate, foundational, and pointed toward one goal - advancing the science of safe, deterministic agents for the world’s most complex industries.

EmphyCorp Inc. www.EmphyCorp.com a private corporation, with several
De-Risked late-stage patented drugs for a Non-Steroidal Bronchodilator Nasal Spray Drugs that simultaneously
treats several medical endpoints including Chronic Coughing, Uncontrolled Coughing, Low Oxygen,
Shortness of Breath, Fatigue and by increasing the synthesis of Nitric Oxide, kills viruses, bacteria, and
fungi in the nasal passages. To date, Emphycorp has successful completed (24) human Clinical Studies which
include Phase 2 and Phase 3 Clinical Trials for Interstitial Lung Disease (Pulmonary Fibrosis with COPD, Idiopathic
Pulmonary Fibrosis-IPF Coughing and Improved Lung Function, CF), Core Respiratory Diseases (COPD,
Asthma), Allergic Rhinitis, Sinusitis, Long COVID, Flu, and COVID-19 treatments. EmphyCorp has Orphan Drug
Designation for all Interstitial Lung Diseases.

Our global team provides unmatched expertise in energy trading and risk management. Our goal is to provide end-to-end IT solutions customized to your needs, delivering projects on-time and on-budget so that you can focus on making your trading business thrive.

Faraday Future is a California-based global intelligent Company founded in 2014 and is dedicated to reshaping the future of mobility through vehicle electrification, intelligent technologies, and AI innovation. Its flagship vehicle, the FF 91, began deliveries in 2023 and reflects the brand’s pursuit of ultra-luxury, cutting-edge technology, and high performance. FF’s second brand, FX, targets the high-volume mainstream vehicle market. Its first model, Super One, is positioned as a first-class EAI-MPV, with fast first deliveries planned to begin in 2026. FF recently announced its entry into the Embodied AI Robotics business, with sales and deliveries beginning in February 2026, marking a new chapter in its strategy to usher in a new era of EAI vehicles and EAI robotics. Learn more at: https://robotics.ff.com/us/ 

Fortitude Mining approaches token mining with a venture mindset, focusing on digital assets with high long-term growth potential. We are committed to advancing the development of the cryptocurrency ecosystem and creating lasting value for our partners through diversified mining opportunities.

With a foundation built on deep industry experience, solid investor support, and the DCG network of brands, we provide reliable and innovative mining operations across a range of digital assets.

Giftpack is the world's leading Emotional Intelligence platform for business success, serving 1,400+ companies with AI-powered relationship automation. Our intelligent infrastructure transforms how enterprises build loyalty, retain talent, and strengthen partnerships through personalized rewards and recognition. With global reach across multiple countries and seamless integrations to CRM and HRIS systems, we automate meaningful connections that drive measurable business outcomes. From employee onboarding to client retention, Giftpack helps companies build authentic relationships while achieving exceptional recipient satisfaction.

GloFa unites and inspires global sports fans through real connections, authentic storytelling, and unique culture-driven experiences. Powered by our Relationship Experience (RX) model, we go beyond surface-level engagement—creating long lasting bonds, a growing community, and amplifying the passion and emotional journeys that connect fans globally. Our mission is to empower creators, engage communities, and redefine what it means to be a sports fan.

GrayMatters Health (GMH)  is a mental health technology company developing and marketing an interventional psychiatry suite of treatments and solutions powered by digital fMRI-Informed biomarkers. Prism™ self-neuromodulation empowers patients to discover personal mental strategies to regulate brain activity associated with their disorder in the clinic and in their daily lives. The Prism platform is being used to treat PTSD (FDA 510(k) cleared) and help patients live better with Depression.

Grayscale is the world’s largest digital asset-focused investment platform* with a mission to make digital asset investing simpler and open to all investors. Founded in 2013, Grayscale has been at the forefront of bringing digital assets into the mainstream. The firm has a long history of firsts, including launching the first Bitcoin and Ethereum exchange traded products in the United States. Grayscale continues to pioneer the asset class by providing investors, advisors, and institutional allocators with exposure to more than 45 digital assets through a suite of over 40 investment products, spanning ETFs, private funds, and diversified strategies. For more information, please follow @Grayscale or visit grayscale.com.

Helio is pioneering a new class of energy infrastructure-space-based power systems aka "Power plants in space" that captures solar energy beyond Earth's atmosphere and beams it safely and efficiently to the surface. Our vision is to establish orbital energy platforms as a foundational layer of the global power grid, delivering uninterrupted, carbon-free electricity at scale and reshaping how nations power cities, industries, and critical systems. Founded in 2018 as the 'problem solvers to the space industry,' Helio designs and delivers world-class space mechanisms, advanced antenna systems, and space design solutions; supporting NASA, private companies, universities, and global space agencies across missions ranging from small-scale programs to flagship space initiatives. We are proud to be a trusted partner to over a dozen space agencies, organizations, and companies across the globe. Our products can be found operating from the Sun to Jupiter. From NASA and European Space Agency to emerging private aerospace firms and academic institutions, we collaborate with some of the most innovative and forward-thinking players in the space industry.

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
View

Intelligent Protection Management Corp. (Nasdaq: IPM) is a managed technology solutions provider focused on cybersecurity and cloud infrastructure. IPM provides dedicated server hosting, cloud hosting, data storage, managed security, backup and disaster recovery, and other related services, including consulting and implementing technology solutions for enterprise and commercial clients across the United States. IPM's other products include ManyCam. IPM has an over 20-year history of technology innovation and holds 8 patents. For more information, please visit: www.ipm.com

We’ve reinvented the EV charger by removing the big, the bad, and the ugly. There are no screens or touchpads, no credit card interface, and no charger cables to manage. Our sleek design was created with neighborhoods like yours in mind, so you’ll barely notice we’re there.

JelikaLite is a clinical stage medical technology company developing a transformational neuromodulation platform for unmet needs in developmental pediatric disorders. Our lead product is focused on Autism Spectrum Disorder (ASD).

Kalohexis is a clinical-stage biotechnology company shaping the next era of metabolic disease care by harnessing the melanocortin (MC) system, the body’s natural regulator of metabolic homeostasis, to help people live healthier lives. Kalohexis’ first- and best-in-class therapeutic peptides are designed to safely and effectively drug central melanocortin-3 and -4 receptors (MC3R/MC4R) to treat many metabolic disorders. Kalohexis’ lead pipeline programs are 710GO, an oral dual MC3R/MC4R agonist to induce healthier, more durable weight loss in general obesity, and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in patients with advanced cancers. For more information, visit www.kalohexis.com or follow us on LinkedIn and X.

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class nuclear PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, currently in preclinical development. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. 

 KELLS is a modern AI-powered dental benefit platform built around the needs of today’s health consumers. We offer next-generation digital capabilities that help identify oral diseases early at home, guide users through their care and benefits, and enable real-time consultations with a smooth transition to in-person care when needed. With increased accessibility, transparency and personalization, KELLS empowers individuals to take control of their oral health and brings a modern solution to businesses to improve health outcomes and reduce costs. Learn more at getkells.com.

Kraus Hamdani Aerospace builds AI-powered unmanned aerial technologies for the world’s most critical missions, when communications fail, infrastructure breaks down, and seconds matter. With proven deployments across military and commercial sectors, Kraus Hamdani Aerospace has supported the U.S. Army, U.S. Navy, MARSOC, U.S. Customs & Border Protection, and global energy leaders. Founded in 2016 and headquartered in Emeryville, California, the company operates worldwide.

MAXONA Pharmaceuticals, headquartered in Malvern, PA, is a privately held clinical-stage pharmaceutical company committed to developing the next generation of therapies to help patents maximize life. The company is distinguished by its strong and diversified leadership team with expertise in neuroscience, drug development, drug formulation and delivery technology, clinical trial design and pharmacology to develop patient-centric therapies that are safe, efficacious, clinically proven and trusted by physicians and their patients. The company’s initial focus is on advancing MAX-001 as a safe and highly effective non-opioid option for the treatment of acute and chronic pain.

MindLab is developing a new class of precision-engineered analgesics designed to redefine the clinical utility of morphine. Its lead program, MLB-001, delivers morphine-level pain relief with enhanced duration, reduced dose requirements, and a controlled central nervous system profile that attenuates drug reward signaling. By simultaneously addressing efficacy, safety, and abuse potential, MindLab aims to overcome one of the most persistent challenges in medicine—delivering powerful pain relief without the traditional trade-offs. This approach positions MindLab to transform pain treatment across acute care and high-need conditions where efficacy is essential, but safety and control are non-negotiable.

MVB Financial Corp. (Nasdaq: MVBF) is an innovative bank powering Fintech solutions in payments, card issuance, sponsorship lending and online gaming programs for leading Fintech companies nationwide, while providing traditional retail and commercial banking services within established markets. MVB’s comprehensive platform includes money movement solutions across all modalities and embedded finance capabilities. MVB combines proven Fintech builder/incubator capabilities, innovative culture, regulatory expertise, core banking and AI-driven operational efficiency to enable Fintech partners to navigate complex regulatory requirements while accelerating time-to-market.

Nerdy (NYSE: NRDY) operates a next-generation live tutoring and intervention platform that leverages the power of human expertise with advanced artificial intelligence (“AI”) to personalize learning, accelerate student achievement, and empower educators. Our mission is to transform the way people learn through technology. The Company’s purpose-built proprietary platform leverages technology, including AI, to connect learners of all ages to experts, delivering superior value on both sides of the network. Nerdy’s comprehensive learning destination provides learning experiences across thousands of subjects and multiple formats—including Learning Memberships, one-on-one instruction, small group tutoring, large format classes, and adaptive assessments. Nerdy’s flagship business, Varsity Tutors, is one of the nation’s largest platforms for live online tutoring and classes. Its solutions are available directly to students and consumers, as well as through schools and other institutions. Learn more about Nerdy at https://www.nerdy.com.

Neuropathix is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthrough therapeutics targeting inflammation to treat patients with significant unmet medical needs.

NinjaCat is pioneering the next frontier of marketing technology: Enterprise Marketing AGI. Built for agencies, media companies, and enterprise brands, we’re not just helping teams report on performance—we’re redefining how marketing gets done.

Oova’s clinical-grade hormone test pairs with our AI-powered app to deliver daily, lab-accurate levels of LH, estrogen, and progesterone — in under 10 minutes.

Whether you’re tracking perimenopause or trying to conceive, Oova turns confusion into clarity.

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

Peraso Inc. (NASDAQ: PRSO) is a pioneer in high-performance 60 GHz unlicensed and 5G mmWave wireless technology, offering chipsets, modules, software and IP. Peraso supports a variety of applications, including fixed wireless access, military, immersive video, and factory automation. For additional information, please visit www.perasoinc.com.

PleoPharma, Inc. is a clinical stage development company in the neuropsych and addiction space focused on finding solutions for people suffering from cannabis addiction and other cannabis-related health problems.

The PleoPharma team includes a world class management team and board of directors who have produced multiple high value exits, >50 worldwide product approvals, and 100+ INDs.

For more information on PleoPharma Inc., please visit www.PleoPharma.com or email Dawn Halkuff, head of Investor Relations at dhalkuff@pleopharma.com.

Hai Po Sun and Teddy Cha, the co-founders of PulseData, embarked on a mission to revolutionize the detection and understanding of chronic diseases. Their inspiration came from witnessing their own immediate family members endure the hardships of kidney failure, dialysis, and organ transplants, all of which could have been prevented. Motivated by this personal experience, they abandoned their previous careers in different industries and established PulseData, the sole AI healthcare company dedicated to identifying and predicting the progression of cardiorenal disease.

At PulseData, we provide in-depth insights into individuals' health conditions, offering valuable information that often goes unnoticed or undiagnosed. By partnering with us, healthcare professionals gain access to a clear and ongoing diagnosis of their patients, enabling them to proactively chart paths for improving lives and achieving positive outcomes. Our data and insights are delivered promptly, engineered to avert tragic, avoidable, and costly events on a large scale.

QumulusAI is a vertically integrated AI infrastructure company focused on delivering a distributed AI cloud by innovating around power, data center, and GPU-based cloud services. The company delivers fast access to high-performance computing with enhanced cost control, reliability, and flexibility. Machine learning teams, AI startups, research institutions, and growing enterprises can now scale their AI training and inference workloads quickly and cost effectively. For more information, https://www.qumulusai.com

reAlpha Tech Corp. (Nasdaq: AIRE) is an AI-powered real estate technology company that aims to transform the multi-trillion-dollar U.S. real estate services market. reAlpha is developing an end-to-end platform that streamlines real estate transactions through integrated brokerage, mortgage, and title services. With a strategic, acquisition-driven growth model and proprietary AI infrastructure, reAlpha is building a vertically integrated ecosystem designed to deliver a simpler, smarter, and more affordable path to homeownership. For more information, visit www.realpha.com.

Recycle Track Systems (RTS) provides innovative waste and recycling solutions powered by AI and data-driven insights. Through proprietary products like the Pello smart waste platform and Cycle reverse vending machines, RTS helps businesses, municipalities, and major venues optimize waste diversion, track environmental impact, and engage communities in sustainability efforts. With a presence across North America, RTS is building a smarter, more sustainable future for waste and recycling. Learn more at www.rts.com.

Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies with an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, while reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products.

In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership.

Further information about the Company can be found at https://www.relianceglobalgroup.com.

Scalestack replaces duct-taped GTM with autonomous execution—where trusted actions create compounding impact. Real growth comes from flow, not force.

Securitize is tokenizing the world with $4B+ AUM (as of Nov 2025) through tokenized funds and equities in partnership with top-tier asset managers, such as Apollo, BlackRock, Hamilton Lane, KKR, VanEck and others. Securitize, through its subsidiaries, is a SEC-registered broker dealer, digital transfer agent, fund administrator and operator of a SEC-regulated Alternative Trading System (ATS). Securitize has also been recognized as a 2025 Forbes Top 50 Fintech company. 

Seek Labs is a TechBio company approaching disease differently. We rebuilt the fundamental building blocks of disease response into a programmable system to detect, protect, and counter disease threats. At the core of this system is an AI-powered intelligence layer that transforms raw biology into actionable data, informing two deployment layers across programmable therapeutics and molecular point-of-care diagnostics. The validated deployment layer insights feed back into the core to create a continuous, data-driven improvement loop, transforming how the world can detect and treat disease.

Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.

Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer live better, for longer. Starton’s proprietary technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit www.startontx.com.

Streamex is a real-world asset tokenization company with institutional-grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold-denominated treasury and tokenization technology powering the modern commodities market, Streamex is building a platform to deliver regulated, yield-bearing, and liquid financial products.

Software Coaching On Demand

AI-powered tools for investment advisors and fund managers

We believe data is the defining asset of the modern economy. Yet today, it is fragmented, unverified, and difficult to control. For data to function as a true asset class, it must be governed by the same principles that underpin any valuable resource: ownership, integrity, and enforceable rights.

Vannadium was created to bring those principles to life. Our infrastructure transforms data from a passive record into an active, governed, and monetizable asset — one that organizations can trust, exchange, and value with confidence.

Vaneltix Pharma, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products focused on repurposed products that can be developed through the FDA 505(b)(2) regulatory pathway and other de-risked programs. Vaneltix’s development programs target significant unmet medical need and major market opportunities in urology and women’s health care. Vaneltix’s lead clinical program is Alenura®. For further information, please visit Vaneltix's website at http://www.vaneltix.com.

Use your voice and bioacoustics to capture Heart Rate, Blood Pressure, Rhythm, and Respiratory Metrics from short voice samples—no wearables, no additional hardware.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children. 

OSA affects over 1 billion people worldwide, yet 80% or more remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes of OSA.

Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com. 

Combine the precision of AI with expert human recruiters. Hire, manage, and scale your freelance workforce from a single intelligent platform. 

Z Squared Inc. is a leading digital asset mining company dedicated to generating Dogecoin (DOGE), Litecoin (LTC), and other Scrypt-based altcoins through sustainable and efficient operations. With a strategic focus on leveraging advanced technology and robust infrastructure, Z Squared aims to establish itself as a premier player in the U.S. cryptocurrency mining industry. The company’s mission is to deliver responsible growth while unlocking significant investor exposure to DOGE’s $20 billion-plus market capitalization and the broader altcoin market, positioning itself at the forefront of the evolving digital asset landscape.

Following its announced merger with Coeptis Therapeutics, Inc. on April 25, 2025, Z Squared is poised to become a wholly-owned subsidiary of the rebranded Z Squared, Inc., with an anticipated listing on the Nasdaq Capital Market upon transaction closure in Q3 2025. Led by Chief Executive Officer David Halabu and Chief Operating Officer Michelle Burke, the company will continue to prioritize cutting-edge mining capabilities and operational excellence. By combining strategic expertise with a commitment to innovation, Z Squared is well-positioned to drive long-term value for shareholders while contributing to the advancement of the global cryptocurrency ecosystem.

About ZenaTech; ZenaTech (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical applications for business, government and defense. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive speed, precision, and cost savings. The Company operates through global offices in North America, Europe, Taiwan, and UAE, and is growing its DaaS business and global network of locations through acquisitions.

Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.

After over 40 years of business growth and industry change, Grassi has redefined what it means to be an advisor and accountant to today’s businesses and individuals. We thrive on helping you solve problems, plan for growth and prepare for the future – all while remaining fully committed to reducing your tax liabilities, easing the financial audit process and preserving your wealth.

A cutting-edge communications and digital engagement platform, IBN is a multifaceted content creator, publisher, and news distributor providing tailored Platform Solutions for select private and public companies to amplify visibility and recognition with large, diverse audiences of investors using IBN “Bolt On” Solutions like Brand Awareness Distribution (BAD), IBNAI, IBNTV and IgnitionX (IX).

Layer 8 Security is a cybersecurity consulting, advisory, and technical services firm that arms organizations with practical security, compliance, and privacy strategies. Today’s business environment requires seamless integration with third-party vendors, clients, and partners. Layer 8 Security ensures your information ecosystem is secure, compliant, and resilient to the severity and frequency of a disruption resulting from a cyber-attack. For more information on Layer 8 Security and associated capabilities, please contact us here or visit our website https://layer8security.com/.

We have a strong entrepreneurial culture that’s complemented by the scale and expertise of over 100 worldwide offices. This brings about something quite extraordinary in the insurance business—local partners with the focus and freedom to do what’s right for your business that can also draw on deep global resources to deliver the very best results.

High-impact marketing that drives results

If you expect your marketing to drive revenue growth, you need a partner that knows how to achieve predictable, profitable growth through data-driven marketing strategy and execution. Marketri’s innovative approach unlocks your growth potential, driving high ROI and making a measurable impact.

Nelson Mullins is your go-to law firm for IPOs, secondary offerings, ATMs, SPACs, RTOs and all things securities. With over 1,000 professionals across the United States, Nelson Mullins is your full service legal partner.

We built our business on a simple idea: mission-critical communications deserve personal attention. For over 25 years, that commitment has defined who we are.

As part of TMX Group, we offer something unique. You get dedicated, responsive support backed by the security and integrity of a global market operator. With TMX Newsfile, you don’t have to choose between expert service and market leadership, you get both.

R&J Strategic Communications is a full-service integrated digital marketing and public relations agency specializing in commercial real estate, healthcare, human services and nonprofit communications. With over 35 years of experience, the agency leverages its expertise in creating, implementing, and managing integrated media campaigns across owned, earned, shared and paid channels to elevate brands and businesses. R&J is driven by its mission to Make a Difference for its clients, team and the community.

We combine sophisticated, cost-effective legal counseling with the type of sound practical judgment that comes from hands-on business experience.  We encourage entrepreneurial approaches and creative thinking, while maintaining the utmost in integrity and responsiveness.  RCCB understands and delivers the advice that companies, business executives and investors, as well as individuals and their families, need to realize their hopes and goals.

We’ve been helping our clients rise above their competition for over 25 years because we’re not afraid of a great idea — or the work that comes along with it. Our team loves rising to the challenge to solve the tough problems and ensure you get the most out of your marketing partnership.

Vstock Transfer is an SEC-registered stock transfer firm serving private companies, IPO's and issuers listed on NYSE American, NASDAQ and OTC Markets. We are not just transaction-oriented but solution-focused to help you through every step of the process.

Zarif Law Group is a securities and capital markets law firm representing issuers, sponsors, and investors across SPAC transactions, de-SPACs, PIPEs, IPOs, uplistings, cross-listings, public offerings, and ongoing SEC compliance.
Based in New York and New Jersey, ZLG advises public and private companies from deal inception through post-merger integration and beyond. Our team works closely with clients throughout the full transaction lifecycle, delivering practical, business-oriented legal solutions.

Layer 8 Security is a cybersecurity consulting, advisory, and technical services firm that arms organizations with practical security, compliance, and privacy strategies. Today’s business environment requires seamless integration with third-party vendors, clients, and partners. Layer 8 Security ensures your information ecosystem is secure, compliant, and resilient to the severity and frequency of a disruption resulting from a cyber-attack. For more information on Layer 8 Security and associated capabilities, please contact us here or visit our website https://layer8security.com/.

DLA Piper is a global law firm formed in 2005 from the merger of Gray Cary Ware & Freidenrich, Piper Rudnick, and DLA LLP. Operating under a Swiss Verein structure, it has approximately 4,300 lawyers across over 90 offices in more than 40 countries, making it one of the world's largest law firms by headcount and revenue. The firm offers full-service corporate legal advice, with leading practices in areas such as corporate/M&A and intellectual property. It adopted Microsoft 365 Copilot to enhance productivity. 

Vena is a Microsoft-native Orchestrated Performance Management platform that enables financial and operational planning, consolidation and close, analytics and execution across Microsoft Excel, Power BI, Azure and Fabric. With a governed, AI-ready data foundation and agentic AI embedded in planning workflows, Vena helps organizations make better decisions and execute on time with confidence. Thousands of organizations worldwide rely on Vena to perform better and achieve more. For more information, visit venasolutions.com.